The bottom line is to modernize clinical trials and provide affordable treatment for patients in need.
A new lung cancer treatment trial called Pragmatica-Lung is starting in the US. It is one of the first of its kind, carried out in real clinical conditions, writes New Atlas.
The study was led by the US National Cancer Institute. The essence of the experiment was to study the treatment of two drugs in people with advanced non-small cell lung cancer.
“Non-small cell lung cancer (NSCLC) is a type of lung cancer that makes up about 80% of all cases. It is called ‘non-small cell’ because the cancer cells are larger than small cell lung cancer NSCLC usually grows and spreads more slowly than small cell lung cancer and can be treated with surgery, radiation therapy, chemotherapy or targeted therapy.
In this way, the effectiveness of therapeutic interventions is assessed in real clinical situations.
“The study will examine whether the combination of two FDA-approved drugs, ramucirumab (Cyramza) and pembrolizumab (Keytruda), improves overall survival, compared with standard chemotherapy treatment, in people with advanced NSCL who have failed in previous chemotherapy and immunotherapy,” they said. At the institute.
We are talking about the drugs Ramucirumab. It is a monoclonal antibody directed against solid cancer tumors that prevents the growth of new blood vessels that the tumor needs to grow. And Pembrolizumab is a type of immunotherapy that stimulates the body’s immune system to fight cancer cells.
Recall that earlier scientists managed to prevent cancer in late stages in mice with the help of implants. According to them, this is a powerful way to fight mesothelioma, an aggressive type of lung cancer.
Breathe deeply. How to recognize lung cancer and who is most at risk
news Correspondent.net on Telegram. Subscribe to our channel Athletistic
Source: korrespondent
I am Ben Stock, a passionate and experienced digital journalist working in the news industry. At the Buna Times, I write articles covering technology developments and related topics. I strive to provide reliable information that my readers can trust. My research skills are top-notch, as well as my ability to craft engaging stories on timely topics with clarity and accuracy.